Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bleecker Bio (Formation) Licenses Lynk’s CNS‑Penetrant TYK2 Inhibitor LNK01006 in $605 M Deal

Fineline Cube Dec 11, 2025
Company Deals

Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo‑Free TIL Therapy for Solid Tumors

Fineline Cube Dec 11, 2025
Company Deals

Relation Therapeutics and Novartis Forge $1.7 Billion Alliance for AI‑Driven Atopic Disease Targets

Fineline Cube Dec 11, 2025
Company Deals

Zealand Pharma and OTR Therapeutics Seal $2.5 Billion Metabolic Disease Partnership

Fineline Cube Dec 11, 2025
Company Deals

D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally

Fineline Cube Dec 10, 2025
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025
Company Drug

Shanghai Pharma’s SPH3127 Renin Inhibitor Wins NMPA Approval for Primary Hypertension

Fineline Cube Dec 11, 2025
Company Drug

Sanofi’s Qfitlia Wins China Approval as First Hemophilia siRNA Therapy

Fineline Cube Dec 11, 2025
Company

Merck’s Q2 Sales Surge 31% to USD 14.6B, Led by Keytruda and China Growth

Fineline Cube Jul 29, 2022

US-based Merck, Sharp & Dohme (MSD, NYSE: MRK) reported Q2 2022 global sales of USD...

Company Drug

Takeda’s Alunbrig Prescribed in China for ALK+ NSCLC Treatment

Fineline Cube Jul 29, 2022

Japan-based Takeda Pharmaceutical Co., Ltd (TYO: 4502) announced that its lung cancer therapy Alunbrig (brigatinib)...

Company Deals

Cosmo Pharma’s Winlevi Cream Secures Greater China Licensing Deal with 3SBio

Fineline Cube Jul 29, 2022

Ireland-based Cosmo Pharmaceuticals NV (SWX: COPN) and China’s 3SBio Inc. (HKG: 1530) have signed a...

Company R&D

PerkinElmer and SCUT Launch Joint Translational Medicine Center

Fineline Cube Jul 29, 2022

US-based PerkinElmer and China’s South China University of Technology (SCUT) have officially launched their joint...

Policy / Regulatory

Sun Pharma’s Bicalutamide Supply Suspended in Multiple Chinese Regions

Fineline Cube Jul 28, 2022

India-based Sun Pharma has suspended the supply of its bicalutamide to Beijing, Tianjin, Jilin, Shanghai,...

Company Drug

MabPharm’s CMAB015 Biosimilar Receives NMPA Approval for Clinical Study

Fineline Cube Jul 28, 2022

Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received...

Company Deals

CSPC Jushi Biopharm’s SYSA1801 ADC Secures Licensing Deal with Elevation Oncology

Fineline Cube Jul 28, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its subsidiary, CSPC Jushi Biopharmaceutical Co.,...

Policy / Regulatory

CDE Releases 61st Batch of Generic Reference Preparations, 34 New Specs Added

Fineline Cube Jul 28, 2022

The Center for Drug Evaluation (CDE) has released the 61st batch of chemical generic reference...

Company

Immunochina Pharmaceuticals Secures CAR-T Production License in Beijing

Fineline Cube Jul 28, 2022

Beijing-based Immunochina Pharmaceuticals has obtained a Drug Production License for its chimeric antigen receptor (CAR)...

Company Deals

Kolo Medical Raises RMB 100M in Series B2 to Launch High-Frequency Ultrasound Imaging System

Fineline Cube Jul 28, 2022

Suzhou-based Kolo Medical Inc., a leader in next-generation semiconductor ultrasound CMUT (Capacitive Micromachined Ultrasonic Transducer)...

Company Drug

Nestle Launches China’s First Cancer-Focused FSMP Product Oral Impact Su Yi Su

Fineline Cube Jul 28, 2022

Switzerland-based Nestle announced the launch of China’s first “foods for special medical purposes” (FSMP) product...

Company Digital

Sanofi’s Hornstein Sees China’s Online Hospitals Boosting Digital Health Strategy

Fineline Cube Jul 28, 2022

Sanofi’s outgoing China market president, Pius Hornstein, expressed confidence in the potential of China’s online...

Company Drug

Nuance Pharma Initiates Phase I Study for Ketorolac IV Infusion (NTM-001)

Fineline Cube Jul 27, 2022

China-based Nuance Pharma announced the initiation of subject enrollment and the first drug infusion in...

Company Drug

Henlius Biotech’s HanBeiTai Biosimilar of Avastin Accepted for CDE Review

Fineline Cube Jul 27, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the Center for Drug Evaluation (CDE) has...

Company Deals

CStone Pharmaceuticals and Kindstar Global Partner on Blood Tumor Precision Diagnosis and Treatment

Fineline Cube Jul 27, 2022

China-based CStone Pharmaceuticals (HKG: 2616) announced a strategic collaboration with compatriot firm Kindstar Global (HKG:...

Company Deals

Wanbangde Pharmaceutical to Acquire Consun Pharma Shares in RMB 2.2B Deal

Fineline Cube Jul 27, 2022

China-based Wanbangde Pharmaceutical Group has entered into a non-legally binding letter of intent with Consun...

Company Drug

Brii Biosciences’ COVID-19 Antibody Cocktail Effective Against Omicron BA.4/5 and BA.2.12.1

Fineline Cube Jul 27, 2022

China-based Brii Biosciences Ltd (HKG: 2137) announced that its anti-COVID-19 antibody cocktail amubarvimab + romlusevimab...

Company Deals

CMS Acquires Wuhan YZY Biopharma’s Bispecific Antibody Assets for Fundus Disease

Fineline Cube Jul 27, 2022

China Medical System Holdings (CMS; HKG: 0867) announced an asset transfer agreement with Wuhan YZY...

Company Deals R&D

HitGen and LoQus23 Therapeutics Partner on DNA Encoded Library for Neurodegeneration

Fineline Cube Jul 27, 2022

China-based HitGen Inc. (SHA: 688222) announced a strategic partnership with UK-headquartered LoQus23 Therapeutics Ltd, leveraging...

Company Deals

Roche Diagnostics and Topgen Biopharm Launch Innovation Center in Chongqing

Fineline Cube Jul 27, 2022

Swiss diagnostics giant Roche Diagnostics and China-based Topgen Biopharm announced the establishment of a strategic...

Posts pagination

1 … 574 575 576 … 596

Recent updates

  • Bleecker Bio (Formation) Licenses Lynk’s CNS‑Penetrant TYK2 Inhibitor LNK01006 in $605 M Deal
  • Shanghai Pharma’s SPH3127 Renin Inhibitor Wins NMPA Approval for Primary Hypertension
  • Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo‑Free TIL Therapy for Solid Tumors
  • Relation Therapeutics and Novartis Forge $1.7 Billion Alliance for AI‑Driven Atopic Disease Targets
  • Sanofi’s Qfitlia Wins China Approval as First Hemophilia siRNA Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bleecker Bio (Formation) Licenses Lynk’s CNS‑Penetrant TYK2 Inhibitor LNK01006 in $605 M Deal

Company Drug

Shanghai Pharma’s SPH3127 Renin Inhibitor Wins NMPA Approval for Primary Hypertension

Company Deals

Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo‑Free TIL Therapy for Solid Tumors

Company Deals

Relation Therapeutics and Novartis Forge $1.7 Billion Alliance for AI‑Driven Atopic Disease Targets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.